LLY vs. META: Eli Lilly vs. Meta Platforms Stock Comparison
This page compares Eli Lilly (LLY) with Meta Platforms (META) using performance and risk, profitability, financial strength, growth, dividends, and valuation metrics.
Performance
Cumulative Growth
Trailing Returns
Performance at a Glance
| Metric | LLY | META |
|---|---|---|
| 1-Year Return | 40.51% | -17.97% |
Risk
Drawdown
Risk at a Glance
| Metric | LLY | META |
|---|---|---|
| 1-Year Volatility | 38.09% | 35.59% |
| Beta | 0.51 | 1.25 |
| 3-Month Avg. Volume | 3.19M | 17.05M |
Company Profile
Eli Lilly (LLY) is classified in the Health Care sector (Pharmaceuticals, Biotechnology & Life Sciences), whereas Meta Platforms (META) belongs to Communication Services (Media & Entertainment) — their GICS classifications point to very different parts of the market.
| Profile Item | LLY | META |
|---|---|---|
| Name | Eli Lilly and Company | Meta Platforms Inc Class A |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Communication Services |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Media & Entertainment |
| GICS Industry | Pharmaceuticals | Interactive Media & Services |
| GICS Sub-Industry | Pharmaceuticals | Interactive Media & Services |
| Market Capitalization | 1,010.34 billion USD | 1,439.24 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | June 1, 1972 | May 18, 2012 |
| Security Type | Common Stock | Common Stock |
Valuation
Price-to-Earnings Ratio (TTM)
Both Eli Lilly (LLY) at 40.32 and Meta Platforms (META) at 20.62 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
40.32
- Max
- 77.14
- Q3
- 43.78
- LLY
- 40.32
- Median
- 24.68
- Q1
- 15.27
- Min
- 1.70
META
Media & Entertainment industry group
20.62
- Max
- 71.35
- Q3
- 37.05
- Median
- 21.91
- META
- 20.62
- Q1
- 11.66
- Min
- 1.74
Price-to-Sales Ratio (TTM)
Eli Lilly (LLY) at 13.98 is priced about in line with its industry on P/S ratio, while Meta Platforms (META) at 6.70 sits in the pricier quartile — META costs more per dollar of sales.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
13.98
- Max
- 55.38
- Q3
- 24.42
- LLY
- 13.98
- Median
- 6.98
- Q1
- 3.30
- Min
- 0.01
META
Media & Entertainment industry group
6.70
- Max
- 8.58
- META
- 6.70
- Q3
- 3.91
- Median
- 1.48
- Q1
- 0.55
- Min
- 0.00
Price-to-Book Ratio (MRQ)
Both look rich against book: Meta Platforms (META) at 5.91 sits in the upper P/B ratio quartile, and Eli Lilly (LLY) at 32.45 prices even higher, above its industry range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.45
- LLY
- 32.45
- Max
- 13.23
- Q3
- 6.38
- Median
- 3.46
- Q1
- 1.64
- Min
- -5.17
META
Media & Entertainment industry group
5.91
- Max
- 11.21
- META
- 5.91
- Q3
- 5.56
- Median
- 1.93
- Q1
- 0.82
- Min
- -2.89
Valuation at a Glance
| Metric | LLY | META |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 40.32 | 20.62 |
| Price-to-Sales Ratio (TTM) | 13.98 | 6.70 |
| Price-to-Book Ratio (MRQ) | 32.45 | 5.91 |
| Free Cash Flow Yield | 0.91% | 1.78% |
Profitability
Return on Equity (TTM)
Both companies show strong equity returns, but Eli Lilly (LLY) at 107.46% is the standout with ROE above its industry range; Meta Platforms (META) at 32.93% also sits in the top quartile.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
107.46%
- LLY
- 107.46%
- Max
- 101.32%
- Q3
- 2.92%
- Median
- -31.26%
- Q1
- -62.68%
- Min
- -158.89%
META
Media & Entertainment industry group
32.93%
- Max
- 46.65%
- META
- 32.93%
- Q3
- 16.35%
- Median
- 6.52%
- Q1
- -4.21%
- Min
- -29.59%
Net Profit Margin (TTM)
Both Eli Lilly (LLY) at 34.99% and Meta Platforms (META) at 32.84% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.99%
- LLY
- 34.99%
- Max
- 12.76%
- Q3
- 4.00%
- Median
- 0.00%
- Q1
- -2.26%
- Min
- -11.53%
META
Media & Entertainment industry group
32.84%
- META
- 32.84%
- Max
- 30.77%
- Q3
- 10.51%
- Median
- 3.81%
- Q1
- -3.12%
- Min
- -20.69%
Operating Profit Margin (TTM)
Both Eli Lilly (LLY) at 49.39% and Meta Platforms (META) at 40.62% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
49.39%
- Max
- 100.30%
- LLY
- 49.39%
- Q3
- 4.40%
- Median
- 0.00%
- Q1
- -131.52%
- Min
- -333.43%
META
Media & Entertainment industry group
40.62%
- Max
- 41.37%
- META
- 40.62%
- Q3
- 16.41%
- Median
- 8.47%
- Q1
- -3.09%
- Min
- -26.23%
Profitability at a Glance
| Metric | LLY | META |
|---|---|---|
| Return on Equity (TTM) | 107.46% | 32.93% |
| Return on Assets (TTM) | 20.74% | 16.40% |
| Net Profit Margin (TTM) | 34.99% | 32.84% |
| Operating Profit Margin (TTM) | 49.39% | 40.62% |
| Gross Profit Margin (TTM) | 82.83% | 81.94% |
Growth
Revenue Growth
Revenue Growth at a Glance
| Metric | LLY | META |
|---|---|---|
| 1-Year Revenue Growth | 44.70% | 22.17% |
| 3-Year Revenue CAGR | 31.69% | 19.89% |
EPS Growth
EPS Growth at a Glance
| Metric | LLY | META |
|---|---|---|
| 1-Year EPS Growth | 95.99% | -1.55% |
| 3-Year EPS CAGR | 51.71% | 39.84% |
Financial Strength
Current Ratio (MRQ)
Meta Platforms (META) at 2.35 carries current ratio above its industry’s typical mid-range, while Eli Lilly (LLY) at 1.50 runs in the tighter-liquidity quartile — different working-capital profiles, both worth examining.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.50
- Max
- 24.81
- Q3
- 11.75
- Median
- 5.57
- Q1
- 2.69
- LLY
- 1.50
- Min
- 0.23
META
Media & Entertainment industry group
2.35
- Max
- 4.23
- META
- 2.35
- Q3
- 2.26
- Median
- 1.36
- Q1
- 0.89
- Min
- 0.31
Debt-to-Equity Ratio (MRQ)
Meta Platforms (META) at 0.36 carries an industry-typical debt-to-equity mix, while Eli Lilly (LLY) at 1.39 uses more debt funding than most peers.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.39
- Max
- 1.60
- LLY
- 1.39
- Q3
- 0.68
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
META
Media & Entertainment industry group
0.36
- Max
- 2.46
- Q3
- 1.30
- Median
- 0.54
- META
- 0.36
- Q1
- 0.17
- Min
- 0.00
Financial Strength at a Glance
| Metric | LLY | META |
|---|---|---|
| Current Ratio (MRQ) | 1.50 | 2.35 |
| Debt-to-Equity Ratio (MRQ) | 1.39 | 0.36 |
| Net Debt / EBITDA | 1.05 | 0.05 |
Dividends
Dividend Yield (TTM)
Meta Platforms (META) at 0.37% pays an industry-typical yield; Eli Lilly (LLY) at 0.61% is above its entire peer range — the higher number, but one that calls for a look at payout sustainability before treating it as an advantage.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.61%
- LLY
- 0.61%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
META
Media & Entertainment industry group
0.37%
- Max
- 2.67%
- Q3
- 1.17%
- META
- 0.37%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Meta Platforms (META) at 7.64% keeps its payout in the industry’s typical band, while Eli Lilly (LLY) at 22.13% pays out more than any of its peers — the most stretched cover in its group.
LLY
Pharmaceuticals, Biotechnology & Life Sciences industry group
22.13%
- LLY
- 22.13%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
META
Media & Entertainment industry group
7.64%
- Max
- 57.34%
- Q3
- 24.40%
- META
- 7.64%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividends at a Glance
| Metric | LLY | META |
|---|---|---|
| Dividend Yield (TTM) | 0.61% | 0.37% |
| Dividend Payout Ratio (TTM) | 22.13% | 7.64% |